|
Emcure Pharmaceuticals Ltd. announced its consolidated financial results for the second quarter and half year ended September 30, 2026. The company's revenue from operations at Rs. 28,205 million, growth of 24.3%, while PAT stood at Rs. 3,251 million, up 29.3%. The company's EBITDA was at Rs. 5,748 million, up 30.9%; while R&D investments at Rs. 1,110 million. The company's domestic business grew 12.0% to Rs. 11,553 million, while International business grew 34.5% to Rs. 16,652 million. The company has received 20+ product approvals across developed and emerging markets. Satish Mehta, chairman, managing director and CEO, Emcure Pharmaceuticals Ltd., said, " Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings. Revenue grew 24% year-on-year to Rs. 28,205 million, with India growing 12% and International 34.5%. EBITDA grew 31% to Rs. 5,748 million, with margin at 20.4%, an expansion of about 100 basis points, driven by productivity gains and operating leverage. PAT grew 29% to Rs.3,251 million. We expect business momentum to sustain into H2FY27.”
|